Key result
Hypomagnesemia linked to ~2.1-fold higher odds of clinically significant arrhythmias in HFrEF.
Why the study?
The study aimed to evaluate the association between serum magnesium concentration and clinically significant arrhythmias in patients with heart failure with reduced ejection fraction.
Does hypomagnesemia (<0.70 mmol/L) increase the risk of clinically significant arrhythmias in patients with heart failure with reduced ejection fraction (LVEF ≤40%)?
Cross-Sectional (n=185)
No
Does hypomagnesemia (<0.70 mmol/L) increase the risk of clinically significant arrhythmias in patients with heart failure with reduced ejection fraction (LVEF ≤40%)?
In patients with HFrEF receiving contemporary guideline-directed medical therapy, hypomagnesemia affects 15.7% of patients and independently doubles the odds of clinically significant arrhythmias.
Answers are grounded in this paper and cite their sources.
Hypomagnesemia may support arrhythmia risk assessment in HFrEF; leaves open whether repletion reduces events in prospective trials.
Objective: To evaluate the association between serum magnesium concentration and clinically significant arrhythmias in patients with heart failure with reduced ejection fraction. Study Design: Analytical Cross Sectional. Setting: Department of Biochemistry, Shahida Islam Medical and Dental College, Lodhran. Period: October 2025 to February 2026. Methods: Total of 185 adults with confirmed systolic dysfunction (left ventricular ejection fraction ≤40%). Hypomagnesemia was defined as fasting serum magnesium <0.70 mmol/L. Arrhythmia burden was ascertained using standardized electrocardiography and ambulatory rhythm monitoring. Multivariable logistic regression quantified independent associations after rigorous adjustment for demographic, renal, electrolyte, and guideline-directed pharmacological confounders. Statistical significance was considered at p value <0.05. Results: Hypomagnesemia affected 15.7% of participants, while 36.8% exhibited clinically significant arrhythmias, predominantly atrial fibrillation and frequent ventricular ectopy. Unadjusted analysis revealed markedly elevated arrhythmia prevalence (odds ratio: 2.89; p=0.009). Following comprehensive covariate adjustment, low serum magnesium remained independently associated with arrhythmia occurrence (adjusted odds ratio: 2.14; 95% confidence interval: 1.03–4.45; p=0.041). Concomitant reductions in estimated glomerular filtration rate and serum potassium emerged as additional independent predictors. Model diagnostics demonstrated acceptable discriminatory capacity and calibration. Subgroup evaluations confirmed consistent effect modification across renal and diuretic exposure categories. Conclusion: Hypomagnesemia independently predicts a substantially higher arrhythmia burden in systolic heart failure. Systematic magnesium surveillance and targeted repletion constitute pragmatic, cost-effective strategies for arrhythmia risk mitigation.
No takes yet. Share an insight, caveat, or question.
Rimsha Kanwal (2026) conducted a cross-sectional in Heart failure with reduced ejection fraction (LVEF ≤40%) (n=185). Hypomagnesemia (fasting serum magnesium <0.70 mmol/L) vs. Normomagnesemia (fasting serum magnesium ≥0.70 mmol/L) was evaluated on Presence of any clinically significant arrhythmia (atrial fibrillation/flutter, premature ventricular complexes >100/24h, non-sustained VT, sustained VT, or clinically relevant bradyarrhythmias) (Adjusted OR 2.14, 95% CI 1.03–4.45, p=0.041). Hypomagnesemia (<0.70 mmol/L) was independently associated with higher odds of clinically significant arrhythmias in HFrEF patients (58.6% vs 32.7%; adjusted OR 2.14, 95% CI 1.03–4.45, p=0.041).
Synapse has enriched 10 related papers. Consider them for comparative context: